“Assessing the population health impact of market interventions to improve access to antiretroviral treatment,” with Till Barnighausen, Joshua Salomon and Brenda Waning, September 2011, forthcoming in Health Policy and Planning.

“Evolution of Market Exclusivity, Paragraph IV Challenges and Generic Penetration," with Henry Grabowski, Richard Mortimer, Genia Long and Noam Kirson, September 2011, forthcoming in Health Affairs.

“The Market for Pharmaceuticals,” with Fiona Scott Morton, July 2011, forthcoming in Handbook of Health Economics.

“Inefficiencies in technology transfer: theory and empirics," with Marie-Laure Allain and Emeric Henry, March 2011 (previously circulated as “The Timing of Licensing: Theory and Empirics”), CEPR Working Paper 8206.

“The Influence of Intellectual Property Rights on the Geography of Trade in Knowledge-Intensive Goods," with Mercedes Delgado and Anita McGahan, May 2011, (revise and resubmit, Journal of Industrial Economics).

“Investments in Pharmaceuticals Before and After TRIPS," with Anita McGahan, March 2011, forthcoming in Review of Economics and Statistics.

“Strategic Responses to Parallel Trade," 2011, B.E. Journal of Economic Analysis and Policy: Advances, Vol. 11 : Iss. 2 (Advances), Article 2.

“Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets" (with Brenda Waning, Ellen Diedrichsen, Lyne Soucy, Jenny Hochstadt, Till Barnighausen and Suerie Moon), Globalization and Health 2010, 6:9.

“Parallel Trade in Pharmaceuticals: Firm Responses and Competition Policy," Chapter 13 in International Antitrust Law & Policy: Fordham Competition Law 2009, edited by Barry Hawk (Juris Publishing, New York, 2009).

“Consolidation and Productivity in the Pharmaceutical Industry," with Henry Grabowski, October 2010, forthcoming in Handbook of the Economics of the BioPharmaceutical Industry.

“Comparative advantages of push and pull incentives for technology development: lessons for neglected diseases" with Cheri Grace, in Global Forum Update on Research for Health Volume 6, 2009.

“Does Re-importation Reduce Price Differences for Prescription Drugs? Lessons from the European Union," with Jennifer Allsbrook and Kevin Schulman, Health Services Research August 2008, 43(4), 1308-1324.

“Mergers and Alliances in Pharmaceuticals: Effects on Innovation and R&D Productivity," with Henry Grabowski, in The Economics of Corporate Governance and Mergers, edited by Klaus Peter Gugler and B. Burcin Yurtoglu (Cheltenham, UK: Edward Elgar Publishing, 2008).

“Would Greater Price Transparency and Uniformity Benefit Poor Patients?" with David Ridley, Health Affairs Sept/Oct 2007, 26(5), 1384-1391.

“Generic Competition and Market Exclusivity Periods in Pharmaceuticals," with Henry Grabowski, Managerial and Decision Economics June-August 2007, 28(4-5), 491-502.

"Pharmaceutical Price Controls and Entry Strategies," Review of Economics and Statistics February 2007, 89(1), 88-99

"The Role of Firm Characteristics in Pharmaceutical Product Launches," RAND Journal of Economics Autumn 2006, 37(3), 602-618.

“Objective and Self-Reported Work Performance Measures: A Comparative Analysis," with Glenn Pransky, Ernst Berndt, Stan Finkelstein, Joan Mackell, and Dan Tortorice (2006), International Journal of Productivity & Performance Management 55(5), 390-399.

"Surviving the Gales of Creative Destruction: The Determinants of Product Turnover," with John M. de Figueiredo (2006), Strategic Management Journal 27(3), 241-264.

"Public & Private Spillovers, Location, and the Productivity of Pharmaceutical Research," with Jeff Furman, Iain Cockburn, and Rebecca Henderson, Annales d'Economie et Statistique 2005, 79/80, 165-188.

“Product Launch Decisions by Dominant and Fringe Firms," with John M. de Figueiredo, Best Paper Proceedings of the Academy of Management, 2005.

"Does Locale Affect R&D Productivity? The Case of Pharmaceuticals," Federal Reserve Bank of San Francisco Economic Letter, Nov. 13, 2004.

"The Long Shadow of Patent Expiration: Do Rx to OTC Switches Provide an Afterlife?" with Ernst R. Berndt and Davina Ling, Scanner Data and Price Indexes, edited by Robert Feenstra and Matthew Shapiro (Chicago: University of Chicago Press, 2003), 229-267.

"Deregulating Direct-to-consumer Marketing of Prescription Drugs: Effects on Prescription and Over-the-counter Sales" with Ernst R. Berndt and Davina Ling (2002), Journal of Law and Economics 44 (3), 691-723.

“Did U.S. Bank Supervisors Get Tougher During the Credit Crunch? Did it Matter to Bank Lending?" with Allen N. Berger and Joseph M. Scalise in Prudential Supervision: What Works and What Doesn't, edited by Frederic Mishkin (Chicago: University of Chicago Press, 2001).